BRPI0917000A2 - proteínas conjugadas com eficácia in vivo prolongada - Google Patents

proteínas conjugadas com eficácia in vivo prolongada

Info

Publication number
BRPI0917000A2
BRPI0917000A2 BRPI0917000A BRPI0917000A BRPI0917000A2 BR PI0917000 A2 BRPI0917000 A2 BR PI0917000A2 BR PI0917000 A BRPI0917000 A BR PI0917000A BR PI0917000 A BRPI0917000 A BR PI0917000A BR PI0917000 A2 BRPI0917000 A2 BR PI0917000A2
Authority
BR
Brazil
Prior art keywords
prolonged
vivo efficacy
protein conjugates
conjugates
protein
Prior art date
Application number
BRPI0917000A
Other languages
English (en)
Inventor
Bernd Peschke
Carsten Behrens
Henrik Sune Andersen
Nils Langeland Johansen
Patrick William Garibay
Sonja Bak
Soren Ostergaard
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0917000A2 publication Critical patent/BRPI0917000A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0917000A 2008-08-06 2009-08-06 proteínas conjugadas com eficácia in vivo prolongada BRPI0917000A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161905 2008-08-06
PCT/EP2009/060186 WO2010015668A1 (en) 2008-08-06 2009-08-06 Conjugated proteins with prolonged in vivo efficacy

Publications (1)

Publication Number Publication Date
BRPI0917000A2 true BRPI0917000A2 (pt) 2016-02-16

Family

ID=41334423

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917000A BRPI0917000A2 (pt) 2008-08-06 2009-08-06 proteínas conjugadas com eficácia in vivo prolongada

Country Status (11)

Country Link
US (1) US8865868B2 (pt)
EP (1) EP2323694A1 (pt)
JP (1) JP5977945B2 (pt)
KR (1) KR20110039348A (pt)
CN (1) CN102112157B (pt)
AU (1) AU2009279090A1 (pt)
BR (1) BRPI0917000A2 (pt)
CA (1) CA2733200A1 (pt)
MX (1) MX2011000847A (pt)
RU (1) RU2526804C2 (pt)
WO (1) WO2010015668A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
CN104984319A (zh) 2008-12-19 2015-10-21 巴克斯特国际公司 Tfpi抑制剂和使用方法
TWI504405B (zh) 2009-01-22 2015-10-21 Novo Nordisk Healthcare Ag 穩定的生長激素化合物
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
CN102834109B (zh) * 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
US20130012684A1 (en) * 2010-02-16 2013-01-10 Novo Nordisk A/S Purification Method
ES2621809T3 (es) 2010-03-19 2017-07-05 Baxalta GmbH Inhibidores de TFPI y procedimientos de uso
CN103269720A (zh) * 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
EP2680875B1 (en) 2011-03-02 2019-10-23 Novo Nordisk Health Care AG Coagulation factor-targeting to tlt-1 on activated platelets
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
KR102118729B1 (ko) * 2012-02-14 2020-06-05 옵코 바이오로직스 리미티드 장기 작용 응고 인자들 및 이를 생산하는 방법들
DK2827883T3 (da) 2012-03-21 2019-07-29 Baxalta GmbH Tfpi-inhibitorer og fremgangsmåder til anvendelse
EP2838552A4 (en) 2012-04-19 2016-05-18 Opko Biolog Ltd OXYNTOMODULIN VARIANTS WITH EXTENDED ACTION AND PROCESSES FOR PRODUCING SAME
EP2846824B1 (en) * 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
SG10202010383YA (en) 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
FR3006315B1 (fr) * 2013-05-31 2015-10-02 Centre Nat Rech Scient Microparticules et nanoparticules auto-associatives composees de proteines
FR3011470B1 (fr) 2013-10-09 2017-01-06 Centre Nat De La Rech Scient (Cnrs) Composition antifongique comprenant un agent antifongique et du chitosane hydrophobise
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2016022547A1 (en) * 2014-08-06 2016-02-11 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
KR20170103970A (ko) * 2015-01-23 2017-09-13 노파르티스 아게 개선된 반감기를 갖는 합성 아펠린 지방산 접합체
WO2016203482A2 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
DE68929273T2 (de) 1988-08-24 2001-07-05 American Cyanamid Co Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
DE68929217T2 (de) 1989-03-20 2000-11-30 Gen Hospital Corp Insulinotropes hormon
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
DE69333718T2 (de) 1992-01-14 2005-12-01 Ajinomoto Co., Inc. Gen, das für eine Fisch-Transglutaminase kodiert
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
DE69533606T2 (de) 1994-01-28 2006-03-02 Ajinomoto Co., Inc. Transglutaminase aus japanischer auster
US6100053A (en) 1994-08-26 2000-08-08 Novo Nordisk A/S Microbial transglutaminases, their production and use
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
EP0871712B1 (en) 1995-01-19 2003-08-27 Novozymes A/S Transglutaminases from oomycetes
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
WO1997011178A1 (en) 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CN1231675A (zh) 1996-09-26 1999-10-13 味之素株式会社 修饰的生理活性蛋白及含有该蛋白的药物组合物
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU2712899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
NZ527241A (en) 1998-12-07 2004-12-24 Sod Conseils Rech Applic Analogues of GLP-1
ATE252601T1 (de) 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1198565A1 (en) 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
PL393178A1 (pl) 2000-12-07 2011-02-14 Eli Lilly And Company Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulino-niezależną i kompozycja farmaceutyczna do leczenia pacjentów z otyłością
EP1352062A2 (en) 2001-01-11 2003-10-15 Maxygen Aps Improved growth hormone molecules
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
JP2005525302A (ja) 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
CN1735423A (zh) 2002-04-10 2006-02-15 伊莱利利公司 胃轻瘫的治疗
AU2003221469A1 (en) 2002-04-30 2003-11-17 Bayer Healthcare Llc FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
US7611700B2 (en) 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US7294687B2 (en) 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
JP2007524579A (ja) 2003-02-19 2007-08-30 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
WO2005028516A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1673464A2 (en) 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
BRPI0417717A (pt) 2003-12-18 2007-04-03 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
DK2842576T3 (en) 2004-01-21 2017-10-16 Novo Nordisk Healthcare Ag Transglutaminase-mediated peptide conjugation
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
JP2006273834A (ja) 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US20070244202A1 (en) 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
FR2873624B1 (fr) * 2004-08-02 2006-09-22 Michelin Soc Tech Bourrelet de pneumatique
WO2006013202A2 (en) * 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
WO2006122982A1 (en) 2005-05-20 2006-11-23 Novo Nordisk Health Care Ag New poly(ethylene glycol) derivatives and process for their coupling to proteins
JP5290753B2 (ja) 2005-06-17 2013-09-18 ノボ ノルディスク ヘルス ケア アーゲー 二量体及び多量体ＦＶＩＩａ化合物
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP1919946A1 (en) 2005-08-18 2008-05-14 Novo Nordisk Health Care AG Transglutaminase variants with improved specificity
ES2546282T3 (es) 2006-02-14 2015-09-22 Novo Nordisk Health Care Ag Acoplamiento de polipéptidos en el extremo C-terminal
US9175061B2 (en) * 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
JP2010504281A (ja) 2006-07-27 2010-02-12 エミスフェアー・テクノロジーズ・インク アリールスルファニル化合物、および活性薬剤を送達するための組成物
EP2054435A1 (en) 2006-08-18 2009-05-06 Novo Nordisk Health Care AG Transglutaminase variants with improved specificity
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
EP2059260B1 (en) 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
EP2129218B1 (en) 2007-02-16 2016-10-19 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
EP2340049B1 (en) 2008-09-12 2015-11-11 Novo Nordisk A/S Method of acylating a peptide or protein
TWI504405B (zh) 2009-01-22 2015-10-21 Novo Nordisk Healthcare Ag 穩定的生長激素化合物
US20110306551A1 (en) * 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII

Also Published As

Publication number Publication date
JP2011529948A (ja) 2011-12-15
RU2011106573A (ru) 2012-09-20
WO2010015668A1 (en) 2010-02-11
KR20110039348A (ko) 2011-04-15
CN102112157A (zh) 2011-06-29
AU2009279090A1 (en) 2010-02-11
US8865868B2 (en) 2014-10-21
RU2526804C2 (ru) 2014-08-27
EP2323694A1 (en) 2011-05-25
CN102112157B (zh) 2013-05-29
US20110223151A1 (en) 2011-09-15
MX2011000847A (es) 2011-02-25
JP5977945B2 (ja) 2016-08-24
CA2733200A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
BRPI0917000A2 (pt) proteínas conjugadas com eficácia in vivo prolongada
SMT201500082B (it) Coniugati di oligosaccaride-proteina
BRPI0922989A2 (pt) Liberação sustentada de nutrientes in vivo
DK3118220T3 (da) Protein
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI1009829A2 (pt) combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
BRPI0916931A2 (pt) agentes terapêuticos
DK2280734T3 (da) Faktor-ix-konjugater med forlængede halveringstider
BRPI0814971A2 (pt) Proteína
ATE522136T1 (de) Wirkstoffsuspensionen in glycerin
BR112013014115A2 (pt) conjugados de fornecimento de polinucleotídeos in vivo apresentando ligações enzimáticas sensíveis
BRPI0721216A2 (pt) Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida
BRPI0921947A2 (pt) formulações de proteína terapêutica
GB2462761B (en) Protein formulation
GB0816976D0 (en) Protein
BRPI0909096A2 (pt) uso de conjugados de interleicna-1 no tratamento de diabetes
BRPI0909302A2 (pt) redução de plasmídeos de conjugação em bactérias
BRPI0816364A2 (pt) injetável, solução de injeção e kit de preparação da injeção
FR2936684B1 (fr) Anorak transformable en duvet.
BRPI0917518A2 (pt) formulações de canfosfamida e suas preparações
AT506244A3 (de) Verbindungskörper
BRPI0910484A2 (pt) esqueletos artificiais de proteína
BRPI0911722A2 (pt) conjugado de peptídeo-polímero
FR2935896B1 (fr) Prothese discale en polyetherethercetone.
DK2509593T3 (da) Protein-polymer-konjugater

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/54 (2017.01), A61K 47/64 (2017.01), A61P 7